These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 31259162)
1. Targeting MCF-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion with AHNP Targeted Peptide. Fotoohi-Ardakani G; Kheirollahi M; Zarei Jaliani H; Noorian M; Ansariniyia H Adv Biomed Res; 2019; 8():33. PubMed ID: 31259162 [TBL] [Abstract][Full Text] [Related]
2. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide. Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063 [TBL] [Abstract][Full Text] [Related]
3. Recombinant Production of a Novel Fusion Protein: Listeriolysin O Fragment Fused to S1 Subunit of Pertussis Toxin. Forghani H; Jamshidi Makiani M; Zarei Jaliani H; Boustanshenas M; Zahraei SM Iran Biomed J; 2021 Jan; 25(1):33-40. PubMed ID: 33129237 [TBL] [Abstract][Full Text] [Related]
4. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. Singh R; Dominiecki ME; Jaffee EM; Paterson Y J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111 [TBL] [Abstract][Full Text] [Related]
5. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276 [TBL] [Abstract][Full Text] [Related]
6. Listeriolysin O Causes ENaC Dysfunction in Human Airway Epithelial Cells. Yang G; Pillich H; White R; Czikora I; Pochic I; Yue Q; Hudel M; Gorshkov B; Verin A; Sridhar S; Isales CM; Eaton DC; Hamacher J; Chakraborty T; Lucas R Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29439494 [TBL] [Abstract][Full Text] [Related]
7. Elimination of the listeriolysin O-directed immune response by conservative alteration of the immunodominant listeriolysin O amino acid 91 to 99 epitope. Bouwer HG; Moors M; Hinrichs DJ Infect Immun; 1996 Sep; 64(9):3728-35. PubMed ID: 8751922 [TBL] [Abstract][Full Text] [Related]
8. Rapid purification of recombinant listeriolysin O (LLO) from Escherichia coli. Churchill RL; Lee H; Hall JC J Ind Microbiol Biotechnol; 2005 Aug; 32(8):355-63. PubMed ID: 16052337 [TBL] [Abstract][Full Text] [Related]
9. Rapid Remodeling of the Host Epithelial Cell Proteome by the Listeriolysin O (LLO) Pore-forming Toxin. Malet JK; Impens F; Carvalho F; Hamon MA; Cossart P; Ribet D Mol Cell Proteomics; 2018 Aug; 17(8):1627-1636. PubMed ID: 29752379 [TBL] [Abstract][Full Text] [Related]
10. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors. Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910 [TBL] [Abstract][Full Text] [Related]
11. Listeriolysin O Binding Affects Cholesterol and Phospholipid Acyl Chain Dynamics in Fluid Cholesterol-Rich Bilayers. Kozorog M; Sani MA; Separovic F; Anderluh G Chemistry; 2018 Sep; 24(53):14220-14225. PubMed ID: 29979814 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic Activity of LLO Y406A Is Targeted to the Plasma Membrane of Cancer Urothelial Cells. Resnik N; Tratnjek L; Kreft ME; Kisovec M; Aden S; Bedina Zavec A; Anderluh G; Podobnik M; Veranič P Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805017 [TBL] [Abstract][Full Text] [Related]
13. Directly Observing the Lipid-Dependent Self-Assembly and Pore-Forming Mechanism of the Cytolytic Toxin Listeriolysin O. Mulvihill E; van Pee K; Mari SA; Müller DJ; Yildiz Ö Nano Lett; 2015 Oct; 15(10):6965-73. PubMed ID: 26302195 [TBL] [Abstract][Full Text] [Related]
14. Phosphocholine Antagonizes Listeriolysin O-Induced Host Cell Responses of Listeria monocytogenes. La Pietra L; Hudel M; Pillich H; Abu Mraheil M; Berisha B; Aden S; Hodnik V; Lochnit G; Rafiq A; Perniss A; Anderluh G; Chakraborty T J Infect Dis; 2020 Oct; 222(9):1505-1516. PubMed ID: 31970394 [TBL] [Abstract][Full Text] [Related]
15. [Prokaryotic expression of Listeria monocytogenes (LM) hly and development of monoclonal antibodies against listeriolysin O (LLO)]. Luo Z; Liu R; Zheng S Sheng Wu Gong Cheng Xue Bao; 2009 Nov; 25(11):1652-7. PubMed ID: 20222463 [TBL] [Abstract][Full Text] [Related]
16. Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery. Kim NH; Provoda C; Lee KD Mol Pharm; 2015 Feb; 12(2):342-50. PubMed ID: 25521817 [TBL] [Abstract][Full Text] [Related]
17. Listeriolysin O Pore-Forming Activity Is Required for ERK1/2 Phosphorylation During Cheng C; Sun J; Yu H; Ma T; Guan C; Zeng H; Zhang X; Chen Z; Song H Front Immunol; 2020; 11():1146. PubMed ID: 32582211 [TBL] [Abstract][Full Text] [Related]
18. Listeriolysin O as cytotoxic component of an immunotoxin. Bergelt S; Frost S; Lilie H Protein Sci; 2009 Jun; 18(6):1210-20. PubMed ID: 19472336 [TBL] [Abstract][Full Text] [Related]
19. Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Saito G; Amidon GL; Lee KD Gene Ther; 2003 Jan; 10(1):72-83. PubMed ID: 12525839 [TBL] [Abstract][Full Text] [Related]
20. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Phelps CC; Vadia S; Boyaka PN; Varikuti S; Attia Z; Dubey P; Satoskar AR; Tweten R; Seveau S Vaccine; 2020 Aug; 38(36):5803-5813. PubMed ID: 32684498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]